Docket Number:13A-1001012
Inventor:Che-Kun James Shen、Kuen-Jer Tsai
IP Status:TW I 455714,US 9,186,356
Abstract:
Frontotemporal lobar degeneration (FTLD) is clinically associated with atrophy in the frontal lobe and temporal lobe of the brain. In the over 65 age group, FTLD is the fourth most common cause of dementia after Alzheimer's disease, dementia with Lewy bodies and vascular dementia; in the below 65 age group, it is the second most common cause after Alzheimer's disease. Previous literatures have provided much information regarding the relationship between TAR DNA binding protein (TDP-43) and the functions of neuronal cells. Recently, TDP-43 has also been identified as the major disease protein in kinds of neurodegenerative diseases, such as FTLD. Rapamycin is a mTOR inhibitor and affects the proliferation, cell growth and cell viability. Recently, it has been used on the treatment of cancer therapy, e.g. breast cancer, colon cancer and lung cancer. The FTLD disease mouse model- brain-specific CaMKII-TDP-43 transgenic mice treated with rapamycin and exhibited the improvement of cognition and motor performances. So far, FTLD are still complicatedly neurodegenerative diseases and no effective treatments, we expect rapamycin could provide a novel therapeutic approaches agent on FTLD.
Fields of Application:
The treatment for FTLD
Advantages when compared to the existing technologies:
The solution of unmet need, FTLD
Contact Person:Sue-Ming Chang / 886-2-2787-2600 / name4517@gate.sinica.edu.tw
